GSK3: A Novel Therapeutic Target in NETs?

#1891

Introduction: GSK3 is a serine/threonine-kinase that plays a critical role in cancer. In neuroendocrine tumours (NETs) GSK3 is regularly overactivated.

Aim(s): In this study, we investigated the effects of the GSK3α/β-inhibitor AR-A014418 alone and in combination with lovastatin, everolimus or 5-fluorouracil (5FU) in human pancreatic (BON1, QGP1) and pulmonary (H727) NET cell lines.

Materials and methods: MTS assay, Western blot analysis, FACS, caspase and migration assays were performed to study cell viability, signalling pathways, apoptosis, cell cycle and migration.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Nölting S

Authors: Weis C, Aristizabal Prada E, Maurer J, Spöttl G, Grossman A,

Keywords: GSK3-inhibition, neuroendocrine tumors, combination treatment,